It’s great to see we are entering our phase 3 pivotal study for GBM Agile and fir FDA approval and this process is agile meaning it reports from the moment we have first data and in reality we may not need that many patients.
which is why recruiting has started and the required numbers are reported as 50-200 patients that’s very different from traditional study that require a set amount of patients - we have a broad range due to the agile nature of the study
and we are heavily subsidised by GCAR and the benefits of the study strategy are appreciated by investors hence the meteoric rise in SP
the market seems to be finally waking up
KZA Price at posting:
$1.37 Sentiment: Buy Disclosure: Held
